Halozyme Therapeutics (HALO) P/E (2011 - 2026)
Halozyme Therapeutics (HALO) P/E from Mar 31, 2011 to Jul 21, 2026. The TTM Halozyme Therapeutics (HALO) P/E is 26.56. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Halozyme Therapeutics (HALO)
| Year | P/E | Change |
|---|---|---|
| 2026 | 26.56 | +4.67% |
| 2025 | 25.38 | +87.42% |
| 2024 | 13.54 | -29.87% |
| 2023 | 19.31 | -47.72% |
| 2022 | 36.93 | +162.53% |
| 2021 | 14.07 | -68.83% |
| 2020 | 45.12 | -226.32% |
| 2019 | -35.72 | +36.00% |
| 2018 | -26.27 | -14.13% |
| 2017 | -30.59 | +70.59% |
| 2016 | -17.93 | -73.84% |
| 2015 | -68.54 | +288.21% |
| 2014 | -17.65 | -13.56% |
| 2013 | -20.42 | +44.76% |
| 2012 | -14.11 | -97.65% |
| 2011 | -600.01 | N/A |
Comparison Halozyme Therapeutics (HALO) P/E with competitors
Halozyme Therapeutics (HALO) P/E is 26.56.